Our Scientific Mission
At Peptigenix, we are dedicated to advancing the science of peptide-based therapeutics. Our mission is to investigate how peptides—through thoughtful design and rigorous testing—may help unlock new treatment pathways for complex and underserved medical conditions. We believe in a data-driven, biology-informed approach that puts safety, precision, and translational potential at the core of every program we pursue.
Exploring the Therapeutic Potential of Peptides
Our
Focus
Peptigenix is focused on the preclinical and early-stage development of peptide-based compounds targeting serious and underserved conditions.
Our
Principle
Our research is guided by the principle that well-characterized peptides—designed and tested with precision—may hold promise in addressing disease pathways that have proven resistant to conventional interventions.
Investigational Research in Cancer Cachexia
Current Program:
PEPTI-101
Our lead research program, PEPTI-101, is an investigational compound currently under development. The program is focused on evaluating the potential role of peptides in modulating immune and metabolic pathways associated with cancer cachexia.
What is Cancer Cachexia?
Cancer cachexia is a complex, multifactorial syndrome characterized by involuntary weight loss, muscle wasting, and systemic inflammation in patients with chronic illnesses, especially advanced cancers.
Up to 80%
Of cancer patients are affected by cancer cachexia worldwide.
Over 20%
Of cancer patients may die due to cachexia-related effects.
Source: Marien et al., PubMed, 2023
Ongoing Peptide Research Efforts
The condition significantly compromises quality of life, treatment tolerance, and overall survival, yet current therapeutic options remain limited. Our research seeks to contribute to the understanding of how peptide-based candidates may influence these biological processes.
PEPTI-101 is currently being evaluated in nonclinical models to assess its safety and biological activity. The goal is to inform future clinical development, pending guidance from regulatory authorities.
Component Peptides of PEPTI-101
PEPTI-101 is composed of four peptides that each act as inhibitors of specific ion channels implicated in disease progression, also known as channel blockers:
Chloride Channel Blocker
Reduces inflammation by decreasing pro-inflammatory cytokines (such as IL-6 and TNF-α), potentially limiting muscle breakdown and improving appetite in cancer cachexia.
Sodium Channel Blocker
Modulates inflammatory and metabolic signaling, potentially reducing systemic inflammation that drives muscle loss and energy imbalance in cancer cachexia.
Potassium Channel Blocker
Helps regulate metabolic dysregulation and reduces catabolic processes, potentially preventing muscle wasting associated with cancer cachexia.
Calcium Channel Blocker
Decreases inflammation-driven signaling pathways and cytokine production, potentially preserving lean muscle mass and stabilizing weight in cancer cachexia patients.
PEPTI-101 is an investigational compound. It has not been approved by the FDA and is not available for commercial use. All research activities are conducted under applicable regulatory frameworks.
Data-Driven Development
Our research integrates molecular biology, immunology, and translational pharmacology to guide the development of investigational products. We prioritize clear biological endpoints and well-characterized safety profiles in validated models prior to initiating any clinical activities.
Future Areas of Exploration
While our immediate efforts are centered on PEPTI-101, Peptigenix is also exploring the potential application of peptide-based approaches in other areas of unmet need. These additional areas are currently in exploratory stages and will be disclosed as research progresses.
